Department of Surgery, Seoul National University Bundang Hospital, Seoul, South Korea.
Adv Exp Med Biol. 2021;1187:381-389. doi: 10.1007/978-981-32-9620-6_19.
Monitoring of patient and tumor during chemotherapy is important to determine whether the chemotherapy is effective to the patient. Variants affect drug enzyme activities and altered enzyme activities can be potential predictors for chemotherapeutic agents including cyclophosphamide and paclitaxel. Response to chemotherapy is primarily based on somatic mutations but germline variants may predict cancer cell sensitivity to chemotherapeutic agents. Furthermore, patient's genetic variation of immune system was reported to be associated with drug response and toxicity. Recently, the somaric and germilne genomic variation influences the pharmacokinetics of chemotherapy and these variation can be biomarkers for chemotherapy.
在化疗期间对患者和肿瘤进行监测对于确定化疗对患者是否有效非常重要。变异会影响药物酶的活性，改变的酶活性可能成为包括环磷酰胺和紫杉醇在内的化疗药物的潜在预测因子。化疗反应主要基于体细胞突变，但种系变异可能预测癌细胞对化疗药物的敏感性。此外，据报道，患者免疫系统的遗传变异与药物反应和毒性有关。最近，体细胞和种系基因组变异影响化疗的药代动力学，这些变异可以作为化疗的生物标志物。
